retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity Eli Lilly: GLP-1R/GCGR/GIPR Triagonist Reduces Liver Fat Content by 86% Dual and Triple Gut Peptide

Glucagon naturally increases energy expenditure and fat metabolism

Since the glucose-lowering effects of GIP have been shown to be impaired in patients with T2D, interest has focused on developing antidiabetic therapies based upon the actions of GLP-1 and GIP, the response to which remains intact. To continue reading Log in or register to continue reading

Ridderstrle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC, et al

The need-to-know this morning Roche plans to launch Phase 3 studies of its leading obesity candidate this quarter after reporting that the drug led to significant weight loss in a mid-stage trial

(2014) Body-mass index and risk of 22 specific cancers: a population-based cohort study of 524 million UK adults

According to MEDVis internal patient data, many patients without diabetes who reach and maintain their prescribed GLP-1 dose self-report average losses of around 1-2 lbs per week after the first month, when combined with a reduced-calorie diet and increased physical activity